Plant Name: Xylosalsola arbuscula
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.282E-13 | 2.484E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.974E-12 | 2.602E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.546E-11 | 5.611E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.829E-11 | 5.688E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.080E-10 | 1.383E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.764E-09 | 5.854E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.427E-09 | 6.024E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.018E-09 | 1.034E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.440E-08 | 1.363E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.421E-07 | 1.647E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 9.794E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.482E-06 | 1.186E-03 | AKR1B10, ALDH1A1, CYP1A1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.375E-06 | 1.441E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.375E-06 | 1.441E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.375E-06 | 1.441E-03 | GPBAR1, NR1H4 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 4.562E-06 | 1.910E-03 | CDC25B, CDK9, CYP1A1, CYP1A2, CYP2C19, CYP3A4, HIF1A, POLB, PRKCA, PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.140E-06 | 2.112E-03 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 6.746E-06 | 2.623E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 2.623E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 8.711E-06 | 3.270E-03 | AKR1B10, CYP1A2, CYP1B1, CYP3A4, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.124E-05 | 4.077E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.684E-05 | 5.915E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.976E-05 | 6.829E-03 | NR1H4, PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.356E-05 | 7.894E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0001758; retinal dehydrogenase activity | 2.356E-05 | 7.894E-03 | AKR1B10, ALDH1A1 |
| BP | GO:0009987; cellular process | GO:0001959; regulation of cytokine-mediated signaling pathway | 2.876E-05 | 9.346E-03 | HIF1A, NR1H4, PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 3.140E-05 | 9.767E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.923E-11 | 8.387E-09 | CYP2C9; PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.037E-10 | 9.574E-09 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.059E-09 | 1.898E-07 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.096E-08 | 2.575E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.427E-07 | 1.164E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.673E-07 | 6.904E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.086E-05 | 2.451E-04 | CYP2C9; AKR1B10; PLA2G1B; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.614E-06 | 1.291E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.626E-05 | 3.787E-04 | CYP2C9; PLA2G1B; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.113E-04 | 1.986E-03 | CYP2C9; PRKCA; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.248E-03 | 1.066E-02 | CYP1A1; CYP1B1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.792E-03 | 1.403E-02 | PRKCA; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.536E-03 | 2.374E-02 | CYP1B1; PRKCA; CDC25B |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.498E-03 | 1.806E-02 | NR1H4; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.981E-03 | 2.736E-02 | PRKCA; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.175E-03 | 2.736E-02 | PRKCA; HIF1A |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 4.512E-03 | 2.736E-02 | PLA2G1B; PRKCA |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.736E-03 | 3.271E-02 | PRKCA; HIF1A |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 6.959E-03 | 3.271E-02 | PLA2G1B; PRKCA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.240E-03 | 2.736E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDC25B; HIF1A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |